Home › Funds › Sofinnova Investments, Inc. › DYN

Sofinnova Investments, Inc. position in DYN

DYNE THERAPEUTICS INC · Health Care

Sofinnova Investments, Inc. reported holding 1,658,384 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$36.8M, representing 1.96% of its reported portfolio and ranking #17 among its reported holdings. Sofinnova Investments, Inc. has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.66M sh
Reported value held$36.83M
Portfolio Weight1.96%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Sofinnova Investments, Inc.'s DYN position evolved

Sofinnova Investments, Inc. first disclosed a stake in DYN in Q3 2023 at 685,133 shares (US$6.1M). The position peaked in Q2 2024 at 1,625,703 shares, worth US$57.4M. Across 12 filings, Sofinnova Investments, Inc. increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,658,384 shares valued at US$36.8M — an increase of 24,487 shares quarter over quarter.. Notable position changes include a 91% increase in Q1 2024 (shares rose 24% over the following quarter), a 60% increase in Q3 2025 (shares rose 55% over the following quarter), a 129% increase in Q4 2025 (shares fell 7% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 685.13K $6.14M New
Q4 2023 1.01M $13.48M Add
Q1 2024 1.94M $54.98M Add
Q2 2024 1.63M $57.37M Reduce
Q3 2024 772.07K $27.73M Reduce
Q4 2024 1.07M $25.24M Add
Q1 2025 716.90K $7.50M Reduce
Q2 2025 614.87K $5.85M Reduce
Q3 2025 985.83K $12.47M Add
Q4 2025 2.25M $44.09M Add
Q1 2026 1.63M $29.62M Reduce
Q2 2026 1.66M $36.83M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Sofinnova Investments, Inc. held DYN?

Sofinnova Investments, Inc. has disclosed DYN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Sofinnova Investments, Inc.'s current position in DYN?

As of Q2 2026, Sofinnova Investments, Inc. holds 1.66M shares of DYN (DYNE THERAPEUTICS INC), valued at $36.83M, representing 1.96% of its reported portfolio and ranking #17.

Has Sofinnova Investments, Inc. been buying or selling DYN?

In the latest 13F filing (Q2 2026), Sofinnova Investments, Inc. increased its position in DYN. The position peaked in Q2 2024 at 1.63M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.